Metagenomi, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

MGX$0.70-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2025	2024	2025	2024
Collaboration revenue	$8,659	$11,514	$21,299	$42,681
Operating expenses:
Research and development	25,283	26,256	72,932	86,015
General and administrative	6,215	7,641	20,013	24,944
Total operating expenses	31,498	33,897	92,945	110,959
Loss from operations	(22,839)	(22,383)	(71,646)	(68,278)
Other income (expense):
Interest income	2,214	3,616	7,586	11,526
Change in fair value of long-term investments	—	(2,055)	(1,292)	(2,055)
Other expense, net	(2)	(57)	(80)	(158)
Total other income (expense), net	2,212	1,504	6,214	9,313
Net loss before provision for income taxes	(20,627)	(20,879)	(65,432)	(58,965)
Benefit from income taxes	234	2,106	92	4,305
Net loss	$(20,393)	$(18,773)	$(65,340)	$(54,660)
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale marketable securities	(1)	1,904	(338)	1,736
Comprehensive loss	$(20,394)	$(16,869)	$(65,678)	$(52,924)
Net loss per share attributable to common stockholders, basic and diluted	$(0.55)	$(0.51)	$(1.76)	$(1.73)
Weighted average common shares outstanding, basic and diluted	37,349,449	36,766,309	37,176,361	31,601,825

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.